Sheena Jonathan sold $45K of NTRA
Sheena Jonathan sold 112 shares of Natera, Inc. (NTRA) at an average of $399.97 ($388.20–$400.29) across 2 trades on 2026-11-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
A small insider sell typically has limited price impact but can trigger short‑term scrutiny.
Market read
The filing provides a fresh, albeit minor, data point for traders tracking insider activity.
What to watch
The director retains a large stake (over 200k shares), suggesting continued confidence.
Background
SEC Form 4 filings disclose insider transactions; investors monitor them for potential signals.
Ticker impact
Director Sheena Jonathan sold 112 shares (~$45K) of Natera via a 10b5‑1 plan, reducing her holdings to 217,574 shares.
likely modest pressure as the market prices in the insider sell
A director offloading shares, even in a small amount, can be interpreted as a weak sell signal, especially when disclosed via a Form 4.
Market effects
Minimal; the sale does not affect the broader genetic‑testing sector.
None; impact confined to Natera shareholders.
Low; no systemic effect.
Counterpoint
The sale may be routine under a pre‑arranged plan and not indicative of future performance.
Key entities
- personSheena Jonathan
Director of Natera, Inc.
- companyNatera, Inc.
Genetic testing company listed on NASDAQ under ticker NTRA.



